recent discoveries that multiple NR coactivators appear M. Parker (ICRF) described domain mapping studies that led to the identification of a short NR ''signature'' to be directly involved in chromatin remodeling. While many NR-associated proteins have been identified, the motif sequence present in a variety of coactivators including SRC-1, CBP/p300, TIF-1, TIF-2, and other recep-CREB binding protein (CBP) and its homolog p300, the CBP associated factors P/CAF, and the steroid receptor tor binding proteins. Peptides, including this 10 amino acid segment, block interactions of SRC-1 with recepcofactor SRC-1 and its homologs (e.g., TIF2) have received considerable attention. R. Evans (HHMI/The Salk tors and mutations in the motif block cofactor binding both in vivo and in vitro. However, since this motif is Institute) discussed recent studies that suggest the existence of putative coactivator and corepressor compresent in thousands of proteins, it alone cannot explain the properties of these cofactors. How coactivators plexes. In the first case, a new SRC-1/TIF2 cofactor termed activator of retinoid receptors (ACTR) was defunction may not be as simple as their recruitment to the target template. P. Webb (UCSF) described that fuscribed that functions as a novel histone acetyltransferase (HAT). ACTR, in turn, conscripts both CBP and sions of coactivators such as SRC-1 with yeast Gal4 DNA-binding domains are insufficient to allow this pro-P/CAF and these three proteins form a trimeric activation complex. The link between coactivation and enzytein to function at a UAS binding site. However, in the presence of a cotransfected estrogen receptor (ER) matic activity was established when David Allis first isolated the histone acetyltransferase from tetrahymena ligand binding domain, agonists (but not antagonists) will ''trigger'' Gal4-CBP activation. How such triggering (Brownwell et al., 1996) , which was shown to be homologous to the yeast coactivator, GCN-5, and subsequently occurs is not clear. Perhaps the HAT activity is potentiated by association of the ER with CBP or the LBD to human P/CAF (Wang et al. 1997 ). This was strengthened by the discovery that CBP is itself an intrinsic (ligand binding domain) after binding CBP recruits other factors that can cooperate to promote activation. histone acetylase (Ogryzko et al., 1996; Yang et al., 1996) . Together, these results suggest that at least one Is the role of ligand simply to induce a conformation resulting in coactivator recruitment and release of coreaspect of transcriptional coactivation involves the recruitment by receptors of a multimeric enzymatic compressor? Clearly not in the case of steroid receptors whose DNA binding is ligand dependent (Beato et al., plex to the DNA template. Reciprocally, the search for NR corepressors led to the isolation of the silencing 1995). In the absence of ligand, steroid receptors are sequestered in a complex including heat shock protein mediators, termed SMRT, and N-Cor Hö rlein et al., 1995) . These proteins interact with 90 (hsp90). Ligand is proposed to dissociate the complex and enable receptor dimerization, nuclear transloreceptors in the absence of hormone and act as transcriptional corepressor for the TR, RAR, and other memcation, and DNA binding. As most other receptors are apparently not associated with hsp90 and are constitubers of the family. As described by Evans (and recently published in Cell and Nature), SMRT/N-Cor form comtively localized in the cell nucleus, the common view has been that DNA binding is usually not a ligand-dependent plexes with the yeast homolog of Sin3 (mSin3A) and RPD-3 (HDAC-1), a histone deacetylase (Alland et al., process, a conclusion that is largely supported by in vitro DNA binding experiments. It was therefore somewhat 1997; Heinzel et al., 1997; Nagy et al., 1997) . This work, suggests that transcriptional repression is in part medisurprising when recent in vivo footprinting indicated that also RAR-RXR heterodimers bound to a specific RARE ated by the action of targeted histone deacetylases recruited to promoters by negative regulatory factors.
in the RAR␤ gene promoter in a ligand-dependent manner (Dey et al., 1994; Chen et al., 1996) . In contrast, According to this view, transcriptional regulation by receptors would be controlled by selective recruiting of however, H. Stunnenberg (EMBL, Heidelberg) reported that at least one other receptor, namely the oncogenic corepressors or coactivators in response to hormone. This, in turn, would control the balance of enzymatic variant of TR␣ (v-erbA), can bind in vivo to a newly identified v-erbA responsive element in the carbonic activity in a target promoter. If the scenario established by this model is correct, then histone tails of nucleoanhydrase II gene. As mutations in v-erbA prevent ligand binding, this is a clear example of ligand-independent somes may be sites through which a major signal transduction pathway exerts its regulatory effect.
NR DNA binding. shown that GR regulation at GREs is dramatically influby inhibiting T cell activation by NF-B signaling and enced by the DNA binding site itself. Thus, the nature the AP-1 response pathway. In contrast to this inhibition, of the GRE influences whether GR will activate or repress as reported by B. Thompson (University of Texas, Galgene transcription. The DBD can functionally interact veston), they synergize with the protein kinase A pathwith the N-terminal activation domain to repress its actiway although the basis for this synergism is not clear.
vation function (Lefstin et al., 1994) . Yamamoto continOne clue has come from the study of the expression of ued to present structural data on GR DBD complexes the c-myc gene. While glucocorticoids and retinoids with GRE derived by NMR spectroscopy showing that have previously been shown to lead to rapid downregubinding to a positive GRE induces a conformational shift lation of c-myc, Thompson reported strong synergism in the DNA binding domain primarily involving the D box with forskolin resulting in a near complete loss of c-myc region. Interestingly, DBDs from mutated versions of GR mRNA and protein, presumably functioning as another harboring mutations within the DBD, which previously block to T cell stimulation. M. Karin (UCSD) described were shown to relieve the inhibitory function, are in the a potential basis for steroid inhibition of AP-1-and NF-''active'' conformation even in the absence of DNA as B-mediated transcription. NF-B is activated by proindetermined by NMR. The results emphasize the imporflammatory cytokines, of viral and bacterial infections tance of the DNA as a regulatory signal for NRs. and, interestingly, can protect cells against apoptosis. Glucocorticoids appear to inhibit NF-B in part by elevating the expression of IB␣, a specific inhibitor protein Ten Facts about Fat Orphan receptors provide a continuing source of new reponsible for retaining NF-B complexes in the cytoplasm. Challenging these results, G. Haegeman (Univeropportunity for discovering new ligands and expanding our understanding of the complex nature of endocrine sity of Gent, Belgium) suggested that glucocorticoids may act exclusively in the nucleus to inhibit the transphysiology. Among the most intensively studied over the last several years are the peroxosime proliferatoractivating capacity of the p65 subunit of NF-B. Thus, while cross-regulation between these pathways has activated receptors (PPARs), which are believed to control the expression of genes involved in lipid homeostabeen well described, the molecular basis for this still remains controversial.
sis. W. Wahli (University of Lausanne) described how the PPAR␣ isoform activates gene transcription in reContinuing on the theme of glucorticoid regulation, H. Reichardt (German Cancer Research Center, Heidelsponse to a variety of compounds including hypolipidemic drugs, as well as natural fatty acids. In contrast, berg) described recent studies on the characterization of glucocorticoid receptor-targeted gene mutations in B. Spiegelman (Dana-Farber Cancer Institute) reviewed evidence suggesting the PPAR␥ isoform serves as a mice. Repression of AP-1 does not appear to require classical GRE DNA binding in AP-1 regulated promoters.
master factor for adipoctye differentiation. Despite the plethora of PPAR-activators, it is only recently that PPAR This appears to be the case also for the inhibition of NF-B, as a mutation within the GR DBD dimerization ligands have been identified. In a series of recent studies (see Kliewer et al., 1995, and Forman et al., 1995a) , the motif (D box) does not prevent repression although it effectively blocks GRE binding (S. Okret, Karolinska Inprostaglandin metabolite PGJ2 and the insulin-sensitizing thiozoladinedione (TZD) drugs are described as stitute). As a consequence, such mutations can distinguish between positive regulation through GREs and PPAR␥ ligands. Why activation of PPAR␥ in fat leads to insulin sensitization in muscle remains an unresolved negative regulation of AP-1 and NF-B. Reichardt described a gene replacement approach where a mutation but important medical issue. Spiegelman went on to describe that phosphorylation of PPAR␥ by the MAPthat prevents GRE binding by abolishing dimerization (here referred to as GR dim ) was targeted to the GR locus kinase pathway appears to block adipocyte differentiation. Hence, this cross-regulation may represent a very in mice. Since GR dim is as effective as wild-type GR in blocking AP-1, the experiment selectively investigates important control mechanism that impacts on adipocyte differentiation as well as insulin sensitivity. The ability the in vivo contribution of the GRE-dependent functions of GR. Interestingly, in contrast to the previously deof PPAR␥ to induce terminal adipogenesis raises the possibility that ligand stimulation of this receptor could scribed early perinatal lethality of GR Ϫ/Ϫ mice (Cole et al., 1995) , the GR dim/dim mice are viable, indicating that be beneficial in the treatment of malignancies where the receptor is expressed. Indeed, Spiegelman provided an the GRE binding function of GR is less essential than had previously been expected. Remarkably, several of exciting description of recent experiments demonstrating the expression of PPAR␥ in liposarcomas, breast the phenotypes previously observed in GR Ϫ/Ϫ mice were and colon cancer, and the potential of ␥ activators to cells. This indicates that RAR␣ and RAR␥ require heterodimerization with RXR␣, a conclusion that is further supdramatically slow cell growth in vitro. Walter Wahli described how a variety of eicosanoids and fatty acids ported from gene targeting experiments in mice (see below). Third, and perhaps most striking, targeting itself may function as PPAR␣ ligands, which leads to the unusual and important conclusion that some NRs may can induce functional redundancy. Accordingly, when using synthetic RAR isotype-specific ligands, RAR␥ was interact physiologically with a variety of natural ligands. Furthermore, some of these natural ligands consist of shown to be ineffective in inducing differentiation of F9 cells into parietal endoderm. In contrast, an RAR␥-common dietary nutrients as opposed to classic hormones. This provides a direct link between nutrition and specific ligand was able to induce differentiation in RAR␥ Ϫ/Ϫ cells demonstrating that RAR␥ now had acphysiologic homeostasis.
This problem was further addressed by M. Milburn quired an active role in the targeted cells (Taneja et al., 1996) . This is an important lesson considering the many (Glaxo Wellcome, Inc.) who presented one of the three crystallographic talks at the meeting. Milburn specifiphenotypes of knock-out mice with mild or no phenotypes. The possibility of a similar genetic ''adaptation'' cally described the crystal structure of PPAR␥ in both the presence and absence of cognate ligands. The liin the absence of a particular gene product may have to be considered as a possible explanation for many gand used was one of the TZDs, which bind to PPAR␥ with high affinity. In support of the conclusion that observations. Finally, rescue experiments have proven very useful in this system and have defined specific PPARs are designed to interact with a variety of ligands, Milburn reported that the ligand binding pocket of roles for distinct functional domains, such as the RAR␥ N-terminal AF1 domain. Furthermore, a protein kinase PPAR␥ is unusually large (1300 Å 3 ) and only 40% of this space is filled by the TZD ligand in the PPAR␥ structure.
A phosphorylation site in RAR␣ was shown to be selectively required for parietal endoderm differentiation This clearly indicates that TZD binding only represents one out of several possibilities for ligand binding. In while the corresponding site in RAR␥ is not required.
The results emphasize the role of retinoid receptors as contrast, J. Baxter (UCSF) and Dino Moras (IGBMC, France) described the previously published TR␣-and integrators of multiple signals and stimuli. Chambon continued to report on the impressive RAR␥-structures in which ligands are very tightly fitted in their respective ligand binding pockets (Renaud et amount of data that has now been accumulated on phenotypes in retinoid receptor knock-out mice, including al. Wagner et al., 1995) . It is therefore noteworthy that RAR can also bind two structurally distinct ligands compound knock-outs with targeted mutations in more than one retinoid receptor gene. Many of the deficienwith high affinity, namely all-trans retinoic acid (atRA) and 9-cis RA (9cRA). Moras reported new data on the cies have previously been defined in fetuses from vitamin A-deficient (VAD) dams. While mutations of individ9cRA-bound RAR␥ hence allowing comparison of how the two ligands are associated with the RAR␥ LBD. In ual genes have been shown to result in surprisingly mild phenotypes, most VAD phenotypes are observed in varicontrast to the liganded PPAR␥, both atRA and 9cRA are tightly fitted into the ligand binding pocket of RAR ous combinations of retinoid receptor knock-outs (Kastner et al., 1995) . Furthermore, the results clearly indicate with every atom of the ligands in direct contact with one or more proximal residues. Interestingly, although atRA that RAR/RXR heterodimeric complexes are responsible for vitamin A signaling in vivo (Kastner et al., 1997) . and 9cRA are structurally distinct, when bound, both molecules are distorted by the pocket toward strikingly
Specifically, RXR␣ appears to be the main heterodimerization partner of RARs during embryogenesis. While similar formations. Thus, both receptor and ligand exert reciprocal conformational changes on each other. the function of RXR as an auxiliary partner of many receptors is indicated by the severity of the phenotype observed in RXR␣ Ϫ/Ϫ , RXR␤ Ϫ/Ϫ double mutant mice, The RAR and TR Genetic Battlefield As a reflection of their important regulatory roles during which die around embryonic day 10, it is striking that animals lacking 5 out of 6 RXR alleles, having only a development, retinoids are also potent regulators of complex differentiation events in vitro. For example, single allele of RXR␣, are viable, a quite remarkable demonstration of redundancy (Krezel et al., 1996) . treatment of F9 embryonic carcinoma cells with varying concentrations of RA results in controlled induction of RXR is not only a retinoid receptor which can bind 9-cis RA, but can also function as an unliganded auxiliary primitive, parietal, or visceral endoderm after exposure to RA. While knock-out experiments are usually perprotein required for high affinity DNA binding of many NRs including RAR (Mangelsdorf et al., 1995) . That this formed in whole animals, P. Chambon (IGBMC, Strasbourg) reported on recent gene targeting experiments is an essential function for RXR is clearly demonstrated by many previous experiments including the strong geof RAR␣, RAR␥, and RXR␣ in F9 cells (Taneja et al., 1996; Chiba et al., 1997) . Some of the most striking netic evidence presented above. Paradoxically, however, the role of RXR as a classical signaling receptor conclusions can be enumerated. First, despite the functional similarity of RAR isotypes in vitro and in in vivo has remained less clear. The Chambon lab has now addressed this issue in an experiment utilizing a transfected cells, RAR␣ and RAR␥ mutant cells have distinct effects on F9 cell differentiation. Thus, RAR␣ gene replacement strategy in mice. In these animals, RXR␣ has been manipulated so that a mutation (referred targeted cells were defective in the formation of parietal endoderm and visceral endoderm differentiation was to as RXR␣ o ) inactivated the ligand-dependent transactivation domain AF2 of RXR while sparing the ability to delayed. On the other hand, RAR␥ is required for both primitive and parietal but not visceral endoderm. Secform heterodimers. These animals are not as severely affected as RXR␣ Ϫ/Ϫ mice but do display some of the ond, RXR␣ affects all of the studied processes in F9
RXR␣
Ϫ/Ϫ phenotypes with variable penetrance. In addieither the TR␣1 or TR␣2 isoforms has illuminated the in tion, other abnormalities normally seen in RAR mutant vivo role of each of the isoforms as presented by B. mice were detected, particularly when RXR␣ o was comVennstrom (Karolinska Institute). While the TR␣1 mutant bined with single targeted RAR isotypes. This led to the mice show decreased heart rate and body temperature, conclusion that liganded RXR apparently plays a role as well as a mild hypothyroidism, TR␣2 does not display in retinoid signaling, not only as a heterodimerization any dramatic phenotype. Neither TR␣1 or TR␣2 affects partner, but also as a ligand-activated receptor. Presumsurvival of the animals, and the mice are fertile. The ably the ligand would be identical to 9cRA or an as-yetphenotype of the TR␣1 animals is distinct from preunidentified RXR ligand. Although other explanations viously described TR␤ null mutant mice ascribing unique for these interesting results can not be entirely ruled functions for the two TR genes (Forrest et al., 1996) . out-e.g., that the RXR␣ o mutation affects the ability of Although these data would argue that the TR␣2 isoform the RAR partner to function optimally, these results are does not play a significant role in vivo, a new study from intriguing because they provide the most compelling J. Samarut (CNRS) provides a somewhat surprising twist evidence so far for a role of liganded RXR in vivo.
to the TR story. Accordingly, a TR␣ null mutation, which While it has been presumed that all retinoid receptors inactivates both TR␣1 and TR␣2 isoforms, generates a have been identified, D. Moore (Massachusetts General much more severe phenotype than would be expected Hospital) rattled a provocative sabre at this thesis. The from looking at the relatively mild phenotypes resulting battlefield was defined by the farnesoid X receptor from mutating either TR␣1 or TR␣2. TR␣ null mice are (FXR), which had previously been shown to form a severely growth retarded beginning 1-2 weeks after heterodimer with RXR and to respond positively to both birth and die between 3-5 weeks. Defects include aberjuvenile hormone (JH III) and farnesoic acid (Forman et rent ossification and severely reduced thyroid hormone al., 1995b). Moore now provides evidence that a potent levels. Interestingly, about half of the homozygous anisynthetic retinoid, tetramethyl-tetrahydro-naphthalenylmals could be rescued by administration of thyroid horpropenyl-benzoic acid (TTNPB) is able to activate the mone. Thus, while TR downregulates hormone levels, FXR:RXR heterodimer. Since TTNPB is an extremely as demonstrated previously, these results indicate that potent RAR agonist, the thrust of Moore's argument is TR␣ plays a key role for thyroid hormone production. that perhaps FXR is a new retinoic acid receptor. While Importantly, the results raise new questions regarding direct binding was not established and the activation is the role of the nonliganded TR␣2. approximately 1000-fold less efficient than RAR activation, the results remain provocative as they establish Orphan Receptors-Coup d'Etat that a common synthetic ligand is able to activate two Orphan NRs constitute the majority of the members of markedly distinct receptors. Nonetheless, these results the NR superfamily. Lacking identified ligands, the funcraise the issue as to the nature of the endogenous FXR tions of these proteins are often rather obscure and the ligand and whether or not FXR responds, as suggested available information is often limited to what can be by Moore, to a new vitamin A metabolite and whether assayed in transfected cells and in in vitro experiments. its mutation will explain some features of vitamin A defiGene targeting of orphan receptors can therefore be ciency.
unusually rewarding, as the results have the potential In addition to its role in normal physiology, the retinoic of establishing a physiological basis for continuing analacid receptor can be mutated to an oncogenic form as ysis of these proteins. Two of the earliest orphans to be in acute promyelocytic leukemia (APL), which is associidentified are the two COUPs, TFI and -II (Qiu et al., ated with the t(15;17) translocation by fusion of the PML 1996). These receptors have been shown to efficiently and RAR genes. Expression of the resulting PML/RAR␣ repress activation by several other NRs including RAR, fusion gene in transgenic mice results in a disease ex-TR, and PPAR. COUP is also one of the most evolutiontremely similar to the human one, demonstrating that arily conserved receptors and has a well-characterized formation of the chimeric protein is the molecular basis counterpart in Drosophila (Sevenup). Homologs have of this malignancy (Brown et al., 1997) . As discussed by also been cloned from early metazoans including Hydra H. de The (CNRS), APL is a unique model system in (V. Laudet, CNRS). Remarkably, Laudet reported a strikcancer biology as retinoic acid, which binds the PML/ ing conservation also at the functional level as sug-RAR␣ fusion, leads to clinical remission by inducing gested by the observation that the Hydra COUP homodifferentiation. Despite the effectiveness of this therapy, log is expressed in neurons, the major COUP-expressing patients can become RA-resistant and relapse. The use cell type also in vertebrates. of Chinese herbal medicine in the treatment of APL led S. Tsai (Baylor College of Medicine, Texas) presented to the recent discovery that arsenic trioxide (As) is a interesting data showing that COUPs are indeed key dramatic chemotherapeutic agent. Unlike RA, this new regulators during neuronal development. COUP TFI drug appears to target the PML moiety of the fusion gene targeted mice die soon after birth and display defiprotein to promote its degradation, resulting in apociencies in the formation of cranial nerves IX and X. ptosis and dramatic clinical remission.
These mice also show reduced axonal arborization in Another of the classical NR ligands is thyroid hormone the cervical plexus region. Furthermore, the early charwhose receptors come in two flavors, TR␣ and TR␤. In acterization of the COUP TFII Ϫ/Ϫ mice reveals an early addition, several isoforms exist as a result of alternative embryonic lethal phenotype involving aberrent vascusplicing. In case of TR␣, one isoform binds ligand (TR␣1) larization. Interestingly, COUP TFII expression in the spiwhile a second (TR␣2) lacks ligand binding ability and nal cord is apparently regulated by another evolutionhas been suggested to downregulate hormone-activated TR␣1. Gene targeting that selectively abolished arily conserved regulatory protein, sonic hedgehog (shh) (S. Tsai). Data identifying an shh-responsive element in partially distinct, the two receptors are colocalized in several tissues. Therefore, as reported in several talks, the COUP TFII promoter define this gene as one of the first identified target genes for shh signaling in the develit is notable that ER␣ and ER␤ form heterodimers that can be activated by hormone (M. Parker, E. Enmark, oping central nervous system, a tissue where shh is a key regulator of cell fate specification. and V. Giguere, McGill University). Hence, such heterodimers constitute a novel estrogen-dependent mechaAn important feature of ligands for nucelar receptors is that they are small lipophilic molecules and hence nism for gene regulation in addition to regulation by ER␣ and ER␤ homodimers. While several groups reported particularly useful as pharmaceuticals. As orphan receptors have yet to find their ligands, their potential as that ER␣ and ER␤ respond in a similar way to a variety of tested compounds, differences do exist. For example, targets for drug development remains to be elucidated. However, the following phenotypes resulting from orGiguere showed that 4-hydroxy tamoxifene is a partial agonist for ER␣ but fails to activate ER␤, while another phan receptor gene inactivation illustrate some exciting possibilities in disorders as diverse as neurodegeneraestrogen, Raloxifene, is a more potent antagonist of ER␤ than ER␣. These and other pharmacological differences tive disease and atherosclerosis. First, T. Perlmann (Ludwig Institute/Karolinska Institute) reported on a tarbetween ER␣ and ER␤ may establish a basis for further therapeutic developments of estrogens in the treatment geted mutation of Nurr1, a close relative of NGFI-B/ Nur77 and Nor1/MINOR, resulting in early postnatal of various disorders including breast cancer and osteoporosis. death and complete agenesis of midbrain dopamine cells (Zetterströ m et al., 1997) . These neurons are the Cross-talk between different signaling pathways converging on transcription factors is common, and ER is cells that degenerate in patients with Parkinson's disease. Moreover, heterozygous, otherwise healthy mice not an exception in this respect. Thus, ER␣ can be activated by several nonligand pathways including those showed decreased levels of dopamine, indicating that Nurr1 may play a role also in mature dopamine cells triggered by epidermal growth factor and dopamine. Mutations affecting such regulation have been defined to maintain wild-type levels of the neurotransmitter. In addition to Parkinson's disease, the results have impliincluding a tyrosine residue preceding helix 12 in the AF2 core (M. Parker and B. Katzenellenbogen, University cations for other dopamine-related disorders such as schizophrenia and drug abuse.
of Illinois, Urbana). This tyrosine is a target for phoshorylation in vivo. Its regulatory role is illustrated by mutaSecond, nature itself has helped to provide genetic information on yet another orphan receptor, ROR, which tions that transform ER␣ into a constitutively active receptor also in the absence of estrogens. Continuing on recently was shown to be mutated in ''staggerer'' (sg/ sg) mice (Hamilton et al., 1996) . These animals have the theme of constitutively active receptors, but diverging from ER to yet another orphan receptor, F. Wiebel been extensively studied because of their deficiencies of cerebellar development. An additional function for (Karolinska Institute) reported on data involving OR-1/UR, a close relative of LXR/RLD-1. Coexpression of ROR has now been defined by the study of sg/sg mice which were found to suffer from increased sucseptibility GAL4-fused OR-1 and RXR results in constitutively active transcription from a reporter containing GAL4 DNA for atherosclerosis, presumably due to a decreased level of apo A-I and apo A-II plasma levels (B. Staels). Furtherbinding sites, evidently as a result of heterodimerization. Mutations in the RXR helix 12 did not affect this activity more, transient transfection experiments defined ROR as a direct regulator of the apo A-I gene through a spewhile it was completely abolished by the corresponding mutation in OR1. Furthermore, protease protection excific ROR binding site in the promoter. These results suggest that ROR may be a promising target for drugs periments suggest that the interaction with RXR is responsible for inducing an ''active'' conformation of modulating lipid metabolism.
OR-1. Thus, RXR in effect acts as a ligand for OR1 leading to its activation.
Assault on Estrogen
The activity of other types of receptors, expressed in Considering the continual interest in estrogen receptor neurons of meeting participants, was eventually si-(ER) function over the years, the word ''renaissance'' lenced at the final hour of an intense meeting. As the would perhaps be an exaggeration when describing the weary troops disembarked, Erice was once again reburst of data reported on ER at this meeting. However, turned to its much deserved majesty and tranquility. an increased interest level is quite evident, not the least At the nearby Palermo airport, however, an air traffic stimulated by the recent and quite unexpected identificontroller strike revealed that no individual is truly imcation of a second estrogen binding receptor (ER␤) mune from another's sorrow. However, despite the de- (Kuiper et al., 1996) . This receptor was originally cloned lays and frustration, the feeling was that much had been from a rat prostate cDNA library and sites of ER␤ expresaccomplished and that the field of nuclear receptors sion include the prostate, bone, ovary, bladder, lungs, continues to march at a remarkable pace. and brain. Several groups reported new data on this Although the in vivo distribution of ER␣ and ER␤ is
